Critics of the Inflation Reduction Act claim its provisions—including direct drug price negotiations and changes to Medicare Part D—are driving up costs for patients and limiting their access to essential medications. The restructuring of the program is said to create barriers for seniors and those with low incomes, raising concerns about affordability. Supporters counter that the measures aim to lower long-term expenses, but opponents warn of immediate financial strain on vulnerable populations. The debate highlights tensions between controlling drug prices and ensuring medication availability for those who need them most.
Critics argue that the Inflation Reduction Act is increasing costs and reducing patient access to medications through price negotiations and Medicare Part D restructuring.
